Last reviewed · How we verify

Medice Arzneimittel Pütter GmbH & Co KG — Portfolio Competitive Intelligence Brief

Medice Arzneimittel Pütter GmbH & Co KG pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Vitamin B12, Vitamin B6, Folic acid Vitamin B12, Vitamin B6, Folic acid marketed Vitamin supplement / B-complex combination Nutritional deficiency / Cardiovascular / Neurology
Benzalkonium Chloride-Benzocaine Topical Benzalkonium Chloride-Benzocaine Topical marketed Topical antimicrobial-anesthetic combination Bacterial cell membranes (benzalkonium); sodium channels (benzocaine) Dermatology / Topical antisepsis

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Medice Arzneimittel Pütter GmbH & Co KG:

Cite this brief

Drug Landscape (2026). Medice Arzneimittel Pütter GmbH & Co KG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/medice-arzneimittel-p-tter-gmbh-co-kg. Accessed 2026-05-17.

Related